The FDA Just Cleared a Bispecific and an Anti-CD38 Antibody in One Myeloma Regimen. Now Your Formulation Has to Keep Both Folded.

Three Numbers That Frame the Problem

5 March 2026 is when the FDA cleared a bispecific co-administered with a co-formulated anti-CD38 antibody as one regimen for relapsed myeloma. It sits at the leading edge of a pipeline you already have to plan for.

319+ bispecific antibody candidates were in clinical development worldwide as of January 2025 (BusinessWire / ResearchAndMarkets). Each of them can aggregate, mispair, and fragment in ways a vanilla IgG1 programme never had to chase.

0.17 is the progression-free survival hazard ratio for the teclistamab plus daratumumab combination versus control in MajesTEC-3 (NCT05083169, n=587). An 83% reduction in the risk of progression or death is the kind of result that pulls more multi-entity regimens into your portfolio whether or not your CMC playbook is ready for them.

The clinical signal is settled. The manufacturing question is still open: how do you keep every entity in the vial, or across the regimen, folded, paired, and on spec when the molecule that was stable alone may not be stable in company?

The Shift: From One Target to Two and Three Binders Per Dose

For two decades the discipline ran on a clean unit of work, one antibody against one target on an IgG1 or IgG4 scaffold whose behaviour was, if not easy, at least well characterised. Your stability protocol, release panel, charge-variant method, and shelf-life model all assumed that unit.

Then the unit changed. Bispecifics put two binding arms on one molecule. Biparatopic antibodies aim both arms at two different epitopes of the same target. Co-formulations put two full antibodies in one vial. Trispecifics are already in the clinic: Innovent Biologics IBI3003, a GPRC5D x BCMA x CD3 tri-targeting myeloma engager, won FDA Fast Track in January 2026 and reported an 83.3% overall response rate at the higher dose levels at ASH in December 2025 (BioPharm International; Labiotech).

The market math is plain enough. Industry analysis from ResearchAndMarkets, reported by BusinessWire, projects bispecific antibody clinical trials surpassed 650 in 2025, with Hemlibra and Vabysmo each exceeding $4 billion in 2024 sales. By that same analysis roughly 15 bispecific antibodies are FDA-approved as of 2026, though the exact count ranges from 14 to 17 depending on how you count formats and indications (evitria). Treat that 15 as an estimate. The trajectory is what matters, and it is up.

The science did not keep that pace. It got harder. The format choices that make a bispecific work generate the impurities, aggregates, and incompatibilities your control strategy now has to define.

Format Multiplies Failure Modes

The CMC consequences follow directly from the architecture, so start with what the format actually is. Each design solves a different part of the multispecific problem, and each leaves a different residue for your control strategy to chase.

BiTE (bispecific T-cell engager)

A BiTE is two scFv domains in tandem with no Fc. Small, short-lived in circulation, and intrinsically prone to aggregation and proteolysis because its stability comes from the scFv folds rather than an IgG scaffold. Blinatumomab and tarlatamab live here.

DART (dual-affinity re-targeting molecule)

A DART is a disulfide-stabilised diabody that solves chain pairing by covalent linkage. The covalent tie is the point: it forces the two chains together rather than leaving the pairing to chance.

Appended-IgG / IgG-scFv

An appended-IgG or IgG-scFv keeps the full Fc, and with it the long half-life and FcRn recycling, but grafts on an scFv that is often the weakest-stability element in the whole molecule and a hotspot for aggregation. You buy circulation time and inherit an aggregation liability.

Common-light-chain and Fc engineering

Common-light-chain designs, knobs-into-holes heavy-chain engineering, and charge-pair Fc engineering all attack the mispairing problem at the design stage by forcing one shared light chain and a heterodimeric heavy-chain assembly. The problem moves upstream into the molecule's sequence rather than disappearing.

The byproducts those choices leave behind

The failure modes follow from those choices. In an IgG-like bispecific with two different heavy and two different light chains, assembly is not clean. Random pairing yields mispaired homodimers, half-antibodies, and light-chain swaps. One documented case characterised a novel light-heavy-light chain mispair in a therapeutic bispecific that confounded clone selection and screening (ScienceDirect). Half-antibody and homodimer byproducts appear with high frequency in asymmetric IgG-like production from unbalanced chain expression and incorrect pairing, and clearing them is a core downstream-purification burden (WuXi Biologics).

A single IgG1 programme never carried these product-related impurities. Every one of them has to be identified, quantified, and shown cleared. The control strategy starts not from a clean baseline but from a population of related species that have to be defined and held.

Aggregation Is Not Additive

The intuition built on single molecules breaks here, because stability does not add up.

Stability converges, it does not sum

In antibody co-formulations, stability can converge. The more stable component tends to stabilise the weaker one, while the weaker one destabilises the stronger, and the blend behaves nonlinearly (Molecular Pharmaceutics, Stability Convergence in Antibody Coformulations). A molecule that passed every stability gate on its own can destabilise once it shares a vial, and isolated-component stability data do not predict the mixed behaviour. Characterising each antibody alone and filing two reports does not let you assume the combination is the sum.

Hetero-aggregates are hard to even see

Beyond each molecule's own self-aggregation, two different antibodies can co-aggregate into hetero-aggregates: mixed high-molecular-weight species that are immunogenic and genuinely hard to characterise, because the two partners are so physicochemically similar that pulling them apart analytically takes multi-dimensional LC-MS rather than a single method (Analytical Chemistry, Identification of Hetero-aggregates in Antibody Co-formulations by multi-dimensional LC-MS).

For T-cell engagers, the aggregate is a safety mechanism

For T-cell-engaging bispecifics, high-molecular-weight species are a safety liability as much as a yield problem. Dimerised species can cross-link T-cell receptors and trigger off-target T-cell activation. The aggregate is a potential adverse-event mechanism, which is why regulators expect it defined and controlled rather than waved through.

Cold-chain answers are format-specific

The cold-chain answer is format-specific in ways that will surprise a team carrying over mAb assumptions. In one pharmaceutical bispecific, aggregation driven mainly by dimerisation appeared during freeze-thaw and storage at -20 C but not at -80 C (PubMed). The storage temperature that protects one molecule will not automatically protect the next, so the answer has to be derived per format and per molecule.

The Co-Formulation Trap

Two molecules rarely share one optimal pH, buffer, ionic strength, and excipient set. Each antibody has its own sweet spot, and a single co-formulation is a negotiated compromise. The damage hides inside that compromise.

The buffer that stabilises one fragments another

Buffer and pH choices that stabilise one antibody can fragment another. In one study, arginine, lysine, and NaCl systems drove fragmentation below pH 5.0, while aspartate systems fragmented the molecule above pH 6.5 (Molecular Pharmaceutics, Impact of Excipient Extraction and Buffer Exchange). Polysorbate, the surfactant meant to protect against interfacial aggregation, can break down into products that destabilise the very formulation it was added to defend. Pick the wrong system for the blend and one partner quietly fragments on stability while the other looks fine.

Single-vial co-formulation is real: the proof points

Single-vial co-formulation is real and approvable, and Phesgo is the proof point. Approved 29 June 2020, Phesgo was the first time two full monoclonal antibodies, pertuzumab and trastuzumab, each binding HER2 at a different epitope, were co-formulated with hyaluronidase into one subcutaneous injection, cleared on the FeDeriCa non-inferiority data (ASCO Post; Roche). The current daratumumab co-formulation, Darzalex Faspro, makes the same point on dose and convenience: 1,800 mg of daratumumab plus 30,000 units of hyaluronidase delivered subcutaneously in 3 to 5 minutes against the hours an IV infusion took, now carrying nine myeloma indications (PR Newswire / J&J).

Charge-Variant Control Under ICH Q6B

More chains and more engineered residues mean more charge heterogeneity to characterise and hold to specification. Every additional chain brings more deamidation, more succinimide and isomerisation, more N-terminal pyroglutamate, and more C-terminal lysine heterogeneity. A bispecific with two distinct heavy chains and engineered Fc residues has more sites where these modifications happen than a single IgG1 ever did.

ICH Q6B is firm on this. It expects the manufacturer to define the product's heterogeneity pattern, including the charge-variant distribution, commonly resolved by capillary or imaged capillary isoelectric focusing (cIEF / icIEF), and to demonstrate that the pattern is consistent lot to lot with the material used in clinical studies (FDA; EMA). Potency, identity, and immunochemical properties are all in scope. Stack a second antibody into the vial and you are now resolving and holding two charge-variant fingerprints, plus any hetero-species between them, to spec.

The Control-Strategy Cost

Every entity you add multiplies the work downstream, and that multiplication is the real expense.

The governing frameworks make the expectation explicit. ICH Q5C drives the stability protocol, the accelerated and stress conditions, and the shelf-life justification, and that justification now has to cover every entity and every interaction in the vial or regimen. ICH Q6B requires the heterogeneity pattern defined and shown consistent. ICH Q2(R2) and Q14 govern analytical procedure development and validation, so the more variants and co-formulated species you carry, the more methods you have to build and defend. ICH Q5A(R2) covers viral safety on the cell-culture-derived substance, and ICH Q13 governs continuous manufacturing where the process design supports it.

None of this is hand-wavable. A control strategy that leaves a variant undefined, or that assumes single-molecule stability data covers a blend, is the kind of gap that draws a Major Objection rather than a minor comment. The combinatorial nature of the format zoo is exactly what makes front-loaded literature, precedent, and stability reasoning so valuable, and so slow to do by hand.

How DeepC Does This Work at the Front of the Programme

The multispecific era turned formulation from a single-molecule problem into a combinatorial one. The difficulty is not that the science is unknown. The precedent, the format-specific stability reasoning, the charge-variant strategy, and the freedom-to-operate position on the format itself sit scattered across approved-product labels, patent corpora, antibody-structure databases, and a dozen ICH guidelines, and assembling them for a specific candidate is a months-long hunt that usually happens after a format is already chosen.

DeepC moves that work to the start with its biologics studies, every claim anchored to the Purple Book record, DailyMed label, patent, or structure it came from.

Biologics formulation and CMC study

This study is built for the exact problem this briefing describes. It returns 2 to 4 design candidates (BF01, BF02 and onward), each labelled with its modality, route, and target, setting out the components, the manufacturing process, a stability profile, release specifications aligned to ICH Q6B, and safety notes. Each rationale names the approved biologic it follows and tags every CMC red flag with its severity. Mapped point by point to the failure modes above:

• Format-specific aggregation and charge-variant control: The study explicitly handles bispecific Fc-engineered formulations with format-specific stability and charge-variant control, the exact failure mode this briefing builds: the mispairing, the HMW species, the deamidation and lysine heterogeneity that ICH Q6B demands you define.
• High-concentration and subcutaneous delivery pressure: For the Darzalex Faspro and Phesgo style of single-vial subcutaneous delivery, it covers high-concentration mAb subcutaneous formulations including viscosity management, aggregation pathways, immunogenicity flags, and fill-finish considerations.
• Which excipients are precedented: It checks every excipient against the FDA Inactive Ingredient Database and PharmaExcipients for its maximum level by route, so the compromise formulation a co-formulation forces on you stays inside precedented ranges rather than off the map.
• What approved combination products already do: It draws precedent from approved-product labels through DailyMed, including the excipients each label declares. That is how it pulls the Phesgo and Darzalex Faspro excipient and buffer systems as anchors instead of reasoning from a blank page.
• Severity-ranked surprises caught early: The CMC red flags, each tagged with its severity, are where chain-mispairing burden, hetero-aggregation risk, and buffer incompatibility surface ahead of the lab spend rather than nine months into a stability study.
• Regulatory rigour: Each rationale places the design in the ICH framework: Q5C for stability, Q6B for specifications, Q2(R2) and Q14 for analytical procedure validation and development, and Q5A(R2) for viral safety where relevant. That is the same framework set the control-strategy section above runs on.

Because candidates compare side by side, two candidate formats, say a common-light-chain IgG-scFv against a tandem scFv, can be evaluated against each other before a molecule is committed. Ask it directly what excipient systems approved bispecific antibodies use, and the precedent comes back cited to its source label.

Biologics FTO analysis

The format choice that fixes mispairing is also the format choice that is patented. Knobs-into-holes, common light chain, and charge-pair Fc engineering are exactly where the blocking intellectual property sits, so stability strategy and freedom-to-operate are the same decision made twice when you look at them apart.

The biologics FTO analysis maps that landscape with keyword and sequence-similarity search, and returns 2 to 4 design-around strategies (BFTO01 and onward), each with its own risk rating of low, moderate, or high. It runs bispecific FTO covering the format itself (BiTE, DART, IgG-scFv, common-light-chain), the target combination, and Fc-engineering claims. For an antibody, you submit the VH and VL sequences and the study searches more than 180,000 antibody sequences disclosed in patents and literature (PLAbDab and PLAbDab-nano) for the closest neighbours and the patents that claim them. It anchors to what is already on the market through the approved-product registries and cross-references the clinical pipeline through Open Targets. Run an FTO on a CD3 x CLDN6 bispecific in the IgG-scFv format and the format risk comes back before you have committed engineering effort to a scaffold someone else claims.

Biologics research review

The broader landscape synthesis a CMC team would otherwise spend weeks assembling runs here, in a fixed structure: approved-product landscape, pipeline and competitive intelligence, structural and sequence references, regulatory framework, and open questions. It surveys the approved-product landscape across the FDA Purple Book, the EMA, and FDA cell and gene therapy approvals, filterable by modality, plus the Open Targets therapeutic-antibody pipeline by INN, stage, target, and sponsor, so you know where your format and target actually sit. For structural grounding to stability reasoning, it draws on SAbDab antibody-antigen complexes, the Thera-SAbDab therapeutic catalogue by format and isotype, and UniProt to PDB to AlphaFold cross-references. The regulatory framing comes through a modality-filtered ICH Q5A-E, Q6B, and Q13 guideline search. Survey the bispecific antibody landscape for CD3 against tumour-associated targets and the synthesis arrives anchored rather than assembled from memory.

One throughline ties the three together. The multispecific era made formulation combinatorial, and DeepC puts the precedent extraction, the format-specific stability reasoning, the charge-variant strategy, and the FTO on the format itself at the start of the programme, each claim traceable to the registry, label, patent, or structure it came from.